Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Revenue (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Revenue for 6 consecutive years, with $62.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 8.12% year-over-year to $62.1 million, compared with a TTM value of $201.5 million through Dec 2025, up 0.52%, and an annual FY2025 reading of $201.5 million, up 0.52% over the prior year.
  • Revenue was $62.1 million for Q4 2025 at Cytek Biosciences, up from $52.3 million in the prior quarter.
  • Across five years, Revenue topped out at $62.1 million in Q4 2025 and bottomed at $24.3 million in Q1 2021.
  • Average Revenue over 5 years is $44.3 million, with a median of $45.2 million recorded in 2024.
  • The sharpest move saw Revenue soared 163.23% in 2021, then dropped 7.59% in 2025.
  • Year by year, Revenue stood at $38.9 million in 2021, then increased by 24.28% to $48.3 million in 2022, then grew by 20.48% to $58.2 million in 2023, then dropped by 1.3% to $57.5 million in 2024, then grew by 8.12% to $62.1 million in 2025.
  • Business Quant data shows Revenue for CTKB at $62.1 million in Q4 2025, $52.3 million in Q3 2025, and $45.6 million in Q2 2025.